Navigation Links
Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
Date:1/31/2008

SAN MATEO, Calif., Jan. 31 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. today announced it has entered into manufacturing agreements with Albemarle Corporation and Patheon Inc. The agreements provide for the large-scale clinical production of Varespladib (A-002), which is expected to be necessary in preparation for Anthera's Phase III clinical trials and planned New Drug Application submission to the Food and Drug Administration. Varespladib is Anthera's oral drug candidate for the treatment of cardiovascular disease.

Anthera believes the agreements position the company to:

-- Secure a cost-effective, long-term supply of Varespladib active

pharmaceutical ingredient (API) and tablets.

-- Quickly scale current manufacturing efforts to meet production

requirements, potentially accelerating Varespladib's time-to-market.

-- Reduce manufacturing related risks to the Varespladib clinical program.

-- Ensure a cost-effective transition to registration and commercial

production.

Building on the work done by Anthera's licensor, Eli Lilly, Albemarle will be responsible for process optimization and manufacture of cGMP quantities of the API. Patheon will be responsible for finished tablet production. The agreement also provides an option for the commercial production of Varespladib in the future. Financial terms were not disclosed.

"These agreements with Albemarle and Patheon provide Anthera with key supply chain resources for the manufacture of Varespladib," said Paul F. Truex, President and Chief Executive Officer of Anthera Pharmaceuticals. "We are pleased to have secured outstanding technical organizations with significant commercial expertise that will contribute to the future success of the Varespladib program."

"We're delighted that Anthera has selected Albemarle as its API manufacturing supplier for its next phase of development," said David Clary, Albemarle Division V
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
5. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
6. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
7. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
8. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. Concentra Medical Centers Gears Up for Flu Season to Keep Area Workforce Healthy
11. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... MONROVIA, Calif., July 31, 2014 STAAR Surgical ... manufacturer and marketer of implantable lenses and delivery systems ... quarter ended July 4, 2014 of $20.0 million, a ... quarter of 2013. On a constant currency basis, revenues ... to the second quarter of 2013.  The effect of ...
(Date:7/31/2014)... Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC ) today ... June 30, 2014. Financial Results for the Six ... revenue for the quarter ended June 30, 2014 increased to ... 30, 2013 primarily due to IMBRUVICA ® (ibrutinib) net ... for the six months ended June 30, 2014 increased to ...
(Date:7/31/2014)... 2014  UBM Medica US announces that ... oncologists, presents exclusive slide shows dealing with communication in ... cancer care. Cancer Network, the ... news, blogs, and podcasts about the latest clinical findings. ... , End-of-life care is challenging for even ...
Breaking Medicine Technology:STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6
... SANTA BARBARA, Calif., Dec. 6, 2010 Direct ... has donated critically needed medical supplies to assist cholera ... University Hospital (JUH) in Cap-Haitien. JUH is the main public ... I.V. solutions and supplies will also be distributed to the ...
... DIEGO, Dec. 6, 2010 /PRNewswire/ -- Cylene Pharmaceuticals, ... of their first-in-class CK2 inhibitor at the 52nd Annual Meeting ... on December 4-7 in Orlando, FL, the company announced today. ... on targeting CK2, a protein kinase that is essential for ...
Cached Medicine Technology:CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti 2CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti 3Cylene Selected to Present CK2 Inhibitor Multiple Myeloma Data at American Society of Hematology Meeting 2Cylene Selected to Present CK2 Inhibitor Multiple Myeloma Data at American Society of Hematology Meeting 3
(Date:8/1/2014)... -- Patients with the progressive, deadly respiratory ailment known ... weapon to battle the disease, the U.S. Food and ... a new treatment, an inhaled spray called Striverdi Respimat ... COPD, which is often linked to smoking, involves multiple ... Patients with COPD may experience a number of ...
(Date:8/1/2014)... -- Although many parents worry about their children choking on ... food. Such was the case for 15-month-old Landon ... handful of nuts. "At the time, Landon had a ... related to his illness or choking," recalled his mother, Ula ... become lodged in his windpipe and had to be removed ...
(Date:8/1/2014)... 2014 The North America Endpoint Security ... market in North America with analysis and forecast of ... $3.53 billion in 2014 to $4.77 billion by 2019, ... , Browse through the TOC of the North America ... the in-depth analysis provided. It also provides a glimpse ...
(Date:8/1/2014)... York, NY (PRWEB) August 01, 2014 ... Dentists industry have benefited from innovative technologies that ... that resemble a patient's tooth color. Moreover, the ... dentistry due to age-related tooth ailments. Due to ... decay, many elderly individuals have demanded dental fillings, ...
(Date:8/1/2014)... Scientists at Albert Einstein College of Medicine ... in digestion help keep the intestinal lining intact. The ... could yield new therapies for inflammatory bowel disease (IBD) ... research involved the intestinal microbiome, which contains some 100 ... or preventing disease is a major emerging field of ...
Breaking Medicine News(10 mins):Health News:FDA Approves New Treatment for People With COPD 2Health News:Food Is a Common Choking Hazard for Kids, Doctor Says 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 4Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:'Normal' bacteria vital for keeping intestinal lining intact 2
... March 21 SRI International, an independent nonprofit research and development organization, will present preliminary results of a diagnostic to detect neglected tropical ... Francisco . , ... , , ... ...
... , March 21 "Tonight,s historic vote marks ... of the insurance industry and provide quality, affordable health care ... the determined leadership of President Barack Obama and ... necessary to defeat the special interests and do what is ...
... African American and white cancer patients are treated at ... equal. Published early online in Cancer , a ... suggest that where patients receive care may partly explain ... new study, researchers led by Tracy Onega, PhD, MA, ...
... A look ... you by the health coverage experts at the Center for Children and Families at Georgetown ... (PRWEB) March 22, ... Following Statement on Health Reform Passed by U.S. House of Representatives Today:, , ,The House ...
... , president and founder of the conservative grassroots public policy organization Eagle Forum, made the following remarks after the public announcement that formerly pro-life Democrat Bart Stupak ... ... , ... ...
... the House is expected to approve today, according to Congressman Chaka Fattah (D-PA-02). , ... , , ... ... "Small businesses ...
Cached Medicine News:Health News:SRI International Researchers to Present Work on Early Detection Tool for Neglected Tropical Diseases at 2010 American Chemical Society (ACS) Meeting 2Health News:SRI International Researchers to Present Work on Early Detection Tool for Neglected Tropical Diseases at 2010 American Chemical Society (ACS) Meeting 3Health News:SRI International Researchers to Present Work on Early Detection Tool for Neglected Tropical Diseases at 2010 American Chemical Society (ACS) Meeting 4Health News:SRI International Researchers to Present Work on Early Detection Tool for Neglected Tropical Diseases at 2010 American Chemical Society (ACS) Meeting 5Health News:SRI International Researchers to Present Work on Early Detection Tool for Neglected Tropical Diseases at 2010 American Chemical Society (ACS) Meeting 6Health News:'A Monumentally Important Victory for Our Country' 2Health News:Racial disparities diminish in specialized cancer centers 2Health News:Georgetown University Center for Children and Families Hails Health Reform As Big Win for Children and Families 2Health News:Schlafly: Health Care Vote Set to Expose the Myth of the 'Pro-Life Democrat' 2Health News:Schlafly: Health Care Vote Set to Expose the Myth of the 'Pro-Life Democrat' 3Health News:Rep. Fattah Says Small Businesses in Philadelphia Are Big Winners in Today's Healthcare Reform 2Health News:Rep. Fattah Says Small Businesses in Philadelphia Are Big Winners in Today's Healthcare Reform 3
Lab-Reader...
Fully automatic NRTL and CE certified microplate reader....
The Benchmark Microplate Reader, with its increased wavelength range of 340 to 750 nm and high performance optics, provides flexibility for specialized applications requiring increased linearity, ult...
EL301 Microwell Strip Reader is a portable, rugged, single/dual wavelength photometer designed to measure and interpret the absorbances of microwell strip assays....
Medicine Products: